New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination with other treatment regimens including talimogene laherparepvec, dabrafenib plus trametinib, or low-dose ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

Related Links:

Viviana Anelli, Anita Ordas, Susanne Kneitz, Leonel Munoz Sagredo, Victor Gourain, Manfred Schartl, Annemarie H. Meijer, Marina Mione
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusion: LE with adjuvant radiation seems to offer good locoregional control without reducing the survival and may be an option of treatment for patients with small, superficial AM. However, APR should be offered for patients with locally advanced disease or as a salvage following recurrence.
Source: Nigerian Journal of Clinical Practice - Category: Rural Health Authors: Source Type: research
Optical coherence tomography (OCT) is an imaging technique that allows ophthalmologists to view the eye’s blood vessels, to study the structure of tissues in various clinical and scientific applications. Though this technology is already widely...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Materials Medicine Nanomedicine Oncology Radiology Source Type: blogs
Researchers at the UA Cancer Center hope early-phase clinical trials will lead to new treatment options for melanoma patients with BRAF or MEK mutations.
Source: The University of Arizona: Health - Category: Universities & Medical Training Authors: Source Type: research
Discussion Skin color is primarily due to genetic factors. Melanocytes are usually found in skin in the basal layer of the epidermis which is also where the melanin usually lies. There are a range of normal skin phenotypes that have been described by Fitzpatrick and range from I-VI: I – pale white skin, blond hair, blue eyed, does not tan, always burns II – fair skin, blue eyed, tans poorly, burns easily III – darker white skin, burns initially then tans IV – light brown skin, tans easily, burns minimally V – brown skin, tans darkly easily, burns rarely VI – dark brown skin, alway...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Letters to the Editor Source Type: research
Here are a few I have come across the last week or so. Note: Each link is followed by a title and a few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.General CommentWell the Silly Season has arrived and it is time to have a break. Barring exciting news this will be the last full week with the last regular post on the 22nd December.Enjoy!-----https://www.australiandoctor.com.au/news/dump-apps-automated-instruments-no-good-melanomaDump the apps: automated instruments 'no good for melanoma' Doctors w...
Source: Australian Health Information Technology - Category: Information Technology Authors: Source Type: blogs
Combination therapy with BRAF and MEK inhibitors significantly improves survival in BRAF mutated melanoma patients but is unable to prevent disease recurrence due to the emergence of drug resistance. Cancer st...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Ocular melanoma is a rare but often deadly malignancy that arises in the uvea (commonest primary site), conjunctiva or the orbit. Primary orbital melanoma (POM) is exceedingly rare, with approximately 60 cases...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
AbstractLynch syndrome (LS) is an autosomal-dominant inherited disorder characterized by a predisposition to colorectal cancer and extracolonic cancers (particularly endometrium, ovary, stomach, small bowel, hepatobiliary tract, pancreas, urothelial tract, brain, and skin). Muir –Torre syndrome (MTS) is considered a phenotypical variant of LS, where patients develop sebaceous neoplasms and keratoacanthomas. Currently, only few studies and case reports suggest an association between LS and other skin cancers, such as Bowens’ disease, melanoma and squamous cell carcinoma (SCC). In this case-report we describe the...
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Melanoma | Merck | Pharmaceuticals | Skin Cancer | Study | Yervoy